How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,145 results for

E/M Medical Decision Making

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

8701. HIV antiretroviral treatment: early versus later

therapy and continuing to answer the same questions in the light of newly emerging HIV therapies. Source of funding None stated. Bibliographic details Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. Journal of Acquired Immune Deficiency Syndromes 2005; 39(5): 562-569 PubMedID Other publications of related interest Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (...) HIV antiretroviral treatment: early versus later HIV antiretroviral treatment: early versus later HIV antiretroviral treatment: early versus later Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions

2005 NHS Economic Evaluation Database.

8702. Evaluating rotavirus vaccination in England and Wales. Part II: The potential cost-effectiveness of vaccination

of the base-case results is required. There is insufficient evidence that the base-case QALYs lost are accurate representations of reality in the UK, thus the base-case results cannot be relied upon for decision-making. Validity of estimate of costs The analysis of the costs was performed from the perspective of the NHS. It appears to have included all the relevant categories of cost. A top-down approach was used to estimate resource use and to value costs, and incidence (quantities) and costs were (...) Evaluating rotavirus vaccination in England and Wales. Part II: The potential cost-effectiveness of vaccination Evaluating rotavirus vaccination in England and Wales. Part II: The potential cost-effectiveness of vaccination Evaluating rotavirus vaccination in England and Wales. Part II: The potential cost-effectiveness of vaccination Jit M, Edmunds W J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains

2007 NHS Economic Evaluation Database.

8703. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

assumed an additional mortality of 23% in the first year following transfusion. Measure of benefits used in the economic analysis The measure of health benefit used was the quality-adjusted life-years (QALYs). The evaluation of health states was taken from published studies. The authors reported that some of the quality of life adjustments were derived from patient surveys. The remaining values were determined by consensus of local clinicians and medical decision analysts after they had considered (...) in the present study. Implications of the study The authors did not make any specific recommendations for further research or changes to practice. Source of funding None stated. Bibliographic details Jackson B R, Busch M P, Stramer S L, AuBuchon J P. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43(6): 721-729 PubMedID Other publications of related interest Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers

2003 NHS Economic Evaluation Database.

8704. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses

subjects. Although the authors stated that the results are probably not generalisable to other settings, they reported a two-way sensitivity analysis on key costs in order to assist decision-making in other settings. Concluding remarks: The authors presented a transparent analysis. However, the study does not adequately value the outcomes of the intervention, so the authors' conclusions should be interpreted with care. Funding None stated. Bibliographic details Jakiche R, Borrego M E, Raisch D W (...) The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses Jakiche R, Borrego M E, Raisch D W, Gupchup G V, Pai M

2007 NHS Economic Evaluation Database.

8705. The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies

The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies Hu D, Hook E W, Goldie S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) . The economic study was carried out in the USA. Dates to which data relate The clinical data were derived from studies published between 1979 and 2004. The resources and costs came from sources published between 1996 and 2003. The price year was 2000. Source of effectiveness data The clinical and epidemiological data used in the decision model were the probabilities of: acute chlamydial infection, persistent acute chlamydial infection, acute pelvic inflammatory disease (PID), PID sequelae (chronic pelvic

2006 NHS Economic Evaluation Database.

8706. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer

. However, the use of extensive sensitivity analyses enhances the external validity of the analysis. The authors stated that adjustments in quality of life, to account for the effect the test may have on decision-making for patients and physicians, were not considered. Thus, the benefits might have been underestimated. Implications of the study The study results suggested that the societal benefits and costs of the test are highly influenced by two factors. More specifically, how patients and physicians (...) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer Hornberger J, Cosler L E, Lyman G H Record

2005 NHS Economic Evaluation Database.

8707. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer

for metastatic breast cancer Schulman K A, Stadtmauer E A, Reed S D, Glick H A, Goldstein L J, Pines J M, Jackman J A, Suzuki S, Styler M J, Crilley P A, Klumpp T R, Mangan K F, Glick J H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology (...) educational grant from US Healthcare, Blue Bell, PA, and by Public Health Service Grants (CA15488, CA23318, CA16520, CA42777, CA32102, CA27525, CA13650, CA07190, CA66636 and CA21115) from the National Cancer Institute, the National Institutes of Health, and the Department of Health and Human Services. Bibliographic details Schulman K A, Stadtmauer E A, Reed S D, Glick H A, Goldstein L J, Pines J M, Jackman J A, Suzuki S, Styler M J, Crilley P A, Klumpp T R, Mangan K F, Glick J H. Economic analysis

Full Text available with Trip Pro

2003 NHS Economic Evaluation Database.

8708. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy

Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy Schousboe J T, Ensrud K E (...) for the state of post DFF; 0.753 and 0.813 for the state of post other fracture; 0.67 and 0.68 for the state of post hip fracture; 0.58 and 0.76 for the state of post clinical vertebral fracture; 0.76 and 0.76 for the state of post morphometric vertebral fracture; and 0.41 and 0.60 for the state of post vertebral or hip fracture. Methods used to derive estimates of effectiveness The authors made some assumptions that were used in the decision model. Estimates of effectiveness and key assumptions The drug

2005 NHS Economic Evaluation Database.

8709. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder

Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder Ko Y, Malone D C, Armstrong E P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) -morbidities included urinary tract infections, bone fractures, depression and skin infections. Modelling A decision tree with a 3-month time horizon was developed. A full outline of treatment pathways, including adverse events and outcomes, along with a graphical representation of the model, was reported. Sources searched to identify primary studies The continence rates and adverse event-related discontinuation rates of the drugs were taken from six clinical trials; these were mainly randomised controlled

2006 NHS Economic Evaluation Database.

8710. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients

Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients Kimmel A D, Goldie S J, Walensky R P, Losina E, Weinstein M C, Paltiel A D, Zhang H, Freedberg K A Record (...) agreements from the Centers for Disease Control and Prevention (U64/CCU114927 and U64/CCU119525), and departmental funding from the Department of Population and International Health, Harvard School of Public Health. Bibliographic details Kimmel A D, Goldie S J, Walensky R P, Losina E, Weinstein M C, Paltiel A D, Zhang H, Freedberg K A. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antiviral Therapy 2005; 10(1): 41-52

2005 NHS Economic Evaluation Database.

8711. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

enhances the generalisability of the findings and makes the results more robust. The authors outlined some limitations to their study. Concluding remarks: There were a few limitations to the methodology, so the authors' conclusions should be considered with a degree of caution. Funding Funding received from H. Lundbeck A/S. Bibliographic details Sorensen J, Stage K B, Damsbo N, Le Lay A, Hemels M E. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first (...) care Sorensen J, Stage K B, Damsbo N, Le Lay A, Hemels M E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of escitalopram in comparison with generic citalopram and venlafaxine in the primary

2007 NHS Economic Evaluation Database.

8712. Stereotactic breast biopsy of noncalcified lesions: a cost-minimization analysis comparing 14-gauge multipass automated core biopsy to 14- and 11-gauge vacuum-assisted biopsy

their decisions. The authors suggest that future cost analyses could help drive the market to lower costs of the more expensive vacuum-assisted probes. Source of funding None stated. Bibliographic details Soo M S, Kliewer M A, Ghate S, Helsper R S, Rosen E L. Stereotactic breast biopsy of noncalcified lesions: a cost-minimization analysis comparing 14-gauge multipass automated core biopsy to 14- and 11-gauge vacuum-assisted biopsy. Clinical Imaging 2005; 29(1): 26-33 PubMedID Other publications of related (...) -gauge vacuum-assisted biopsy Soo M S, Kliewer M A, Ghate S, Helsper R S, Rosen E L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of disposable 14-gauge large core needles (Bard, Covington) used with a multipass automated

2005 NHS Economic Evaluation Database.

8713. Cost-effectiveness and contraceptive effectiveness of the transdermal contraceptive patch

, et al. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004;69:189-95. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001;285:2347-54. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system (...) in the USA. Dates to which data relate The effectiveness data came from studies published from 1989 to 2004. No dates for the resource use data were explicitly reported. The price year was 2002. Source of effectiveness data The effectiveness evidence was derived from a synthesis of completed studies and authors' opinions. Modelling The authors stated that a published decision model was used to examine the costs and clinical outcomes associated with COCs and patches in a hypothetical cohort of healthy

2005 NHS Economic Evaluation Database.

8714. Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma

Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma Swigonski N L, Kuhlenschmidt H L, Bull M J, Corkins M R, Downs S M Record Status This is a critical abstract of an economic evaluation that meets (...) data The effectiveness evidence was derived from a synthesis of published studies. Modelling A decision tree model was constructed to assess the costs and benefits associated with CD screening versus no screening in a hypothetical cohort of asymptomatic DS children. The time horizon of the model was lifetime. Regardless of the screening or no screening strategy, children could or could not have underlying CD and develop CD-related complications (lymphoma) or not. In the screening branch, children

2006 NHS Economic Evaluation Database.

8715. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease

Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease van den Akker-van Marle M E, Rijnders M E, van Dommelen P (...) strategy in practice. In addition, the feasibility of the use of the PCR test in Dutch clinical practices needs to be closely monitored to choose the strategy most applicable in this setting. Source of funding Funded by ZON MW. Bibliographic details van den Akker-van Marle M E, Rijnders M E, van Dommelen P, Fekkes M, van Wouwe J P, Amelink-Verburg M P, Verkerk P H. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal

Full Text available with Trip Pro

2005 NHS Economic Evaluation Database.

8716. Postpartum length of stay and newborn health: a cost-effectiveness analysis

Postpartum length of stay and newborn health: a cost-effectiveness analysis Postpartum length of stay and newborn health: a cost-effectiveness analysis Postpartum length of stay and newborn health: a cost-effectiveness analysis Malkin J D, Keeler E, Broder M S, Garber S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) that the study under estimated the true benefit of the mandate. Validity of estimate of measure of benefit The authors estimated discounted life-years gained as a result of the mandate. This was a natural choice of benefit. They thought that the cost per quality-adjusted life-year gained would not be much higher than the cost per life-year gained, and therefore did not make quality adjustments. This decision was made explicitly and was well justified. Validity of estimate of costs The authors reported

2003 NHS Economic Evaluation Database.

8717. Cost-effectiveness of routine endoscopic biopsies for Helicobacter pylori detection in patients with non-ulcer dyspepsia

. Dates to which data relate The effectiveness data were derived from studies published between 1966 and 2003. The price year was 1999. Source of effectiveness data The effectiveness data were derived from a review and synthesis of published studies, supplemented by assumptions made by an expert panel. Modelling A clinical decision-making model was conducted to compare the costs and effectiveness of the two strategies (taking a biopsy for the detection of H. pylori with an RUT, or not taking a biopsy (...) P, Fennerty M. Therapy for Helicobacter pylori in patient with nonulcer dyspepsia. A meta-analysis of randomized controlled trials. Annals of Internal Medicine 2001;134:361-9. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for nonulcer dyspepsia. BMJ 2000;321:659-64. Talley N, Vakil N, Ballaed E, Fennerty M. Absence of benefit of eradication Helicobacter pylori in patients with nonulcer

2003 NHS Economic Evaluation Database.

8718. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine

Goldie S J, Kohli M, Grima D, Weinstein M C, Wright T C, Bosch F X, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Journal of the National Cancer Institute 2004; 96(8): 604-615 PubMedID Other publications of related interest Shireman TI, Tsevat J, Goldie SJ. Time costs associated with cervical cancer screening. Intl J Technol Assess Health Care 2001;17:146-52. Straton K, Durch J, Lawrence R, eds. Vaccines for 21st century, a tool for decision (...) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine Goldie S J, Kohli M, Grima D, Weinstein M C, Wright T C, Bosch F X, Franco E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief

2004 NHS Economic Evaluation Database.

8719. Empirical anti-candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis

. Bibliographic details Golan Y, Wolf M P, Pauker S G, Wong J B, Hadley S. Empirical anti-candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Annals of Internal Medicine 2005; 143: 857-869 PubMedID Other publications of related interest Rex J H, Bennett J E, Sugar A M et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. New England (...) Empirical anti-candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis Empirical anti-candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis Empirical anti-candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis Golan Y, Wolf M P, Pauker S G, Wong J B, Hadley S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

2005 NHS Economic Evaluation Database.

8720. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada

, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etindronate, risendronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;22(1). Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6(29). Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of raloxifene in the UK: an economic (...) myocardial infarction (AMI), unrecognised AMI, angina pectoris, coronary insufficiency, and sudden death. Every year, women could remain in the same health state, move into one of the other health states, or die from "other causes". A simplified structure of the model was represented graphically. Outcomes assessed in the review The outcomes assessed were: the risk of disease events included in the decision model, the mortality risk, the effect of treatment, and the utility weights associated

2006 NHS Economic Evaluation Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>